SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors scrutinize potential Matrix-M partnership developments following an earnings beat, while the community remains sharply divided over governance and the push for leadership changes via upcoming proxy votes. Discussions are heavily focused on the company's licensing platform strategy versus lingering concerns about cash burn and the lack of specific deal disclosures.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the company's global expansion efforts and a massive short interest, which many believe is primed for a potential squeeze. The community is actively tracking Dr. Patrick Soon-Shiong's recent communications, viewing the company's international reach and AI-driven manufacturing as catalysts for future value despite ongoing regulatory volatility.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant investor attention driven by strong Q1 earnings, which highlighted 55% revenue growth and improved margins as the company transitions into a pure-play edge AI and defense-focused business. The community is actively discussing the stock's potential for rerating alongside the broader push for ruggedized, mission-critical AI infrastructure within defense and industrial sectors.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors aggressively price in the company's expanding AI infrastructure footprint and recent strategic acquisitions, with community sentiment driven by a potential short squeeze and anticipation of upcoming earnings. Enthusiastic discussions are centered on the company's competitive positioning as a 'fourth hyperscaler' and its ability to secure major multi-billion dollar contracts, leading to significant momentum that has pushed the stock to new highs.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently at the center of investor focus following a massive 15-year, $9.8 billion AI data center lease, which has sparked a strong rerating narrative as the company shifts from a crypto miner to an AI infrastructure leader. While some community members remain skeptical of the transition and the reliance on major hyperscalers, bulls are aggressively highlighting the stock's long-term potential, leading to intense debates over its valuation and recent parabolic price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing a massive parabolic rally fueled by intense AI-driven demand for memory chips, with the stock recently hitting all-time highs above $1,400. While bulls are celebrating massive gains and pointing to long-term storage shortages, the community is actively debating whether this movement reflects genuine AI-fueled fundamental growth or an unsustainable speculative bubble.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc

Ernexa Therapeutics is seeing heightened activity driven by a new manufacturing collaboration with Cellipont Bioservices intended to advance their ovarian cancer candidate, ERNA-101, into clinical trials. While some investors are optimistic about the potential for a squeeze due to the company's low float and strong institutional presence, others are expressing significant caution regarding the stock's history of dilution and reverse splits.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging as investors pivot toward its potential as an AI infrastructure and power-centric datacenter play, bolstered by a significant expansion in its partnership with AMD. Community sentiment is highly active, with traders closely monitoring technical resistance levels while debating the long-term strategic transformation from pure Bitcoin mining into a critical AI power provider.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing significant volatility as investors debate the potential synergy of its Disney partnership and its upcoming earnings report. The community remains deeply divided between bulls anticipating a short squeeze or profitable turnaround and bears citing ongoing subscriber losses and management's past performance as reasons for further downside.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is experiencing significant upward momentum driven by a major partnership expansion with Hirschbach to deploy hundreds of autonomous trucks, signaling a shift from research to large-scale commercialization. Investors are actively discussing the potential for a short squeeze, citing high short interest and massive insider buying that bolsters confidence in the company's long-term scale and execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax Q1 2026 Earnings Call Transcript

Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of +75.68% and +100.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Its licensing, royalties, and other revenue rose to $97 million in Q1, up from $45 million a year earlier.</li><li>Novavax is targeting a reduction in expenses, aiming for about $325 million in combined research and administrative spending in 2026, and around $225 million in 2027.</li><li>·Q1 net loss came in at $9 million, or a loss of $0.06 per share, significantly narrower than the 0.23 per share estimate.</li></ul>Shares of Novavax (NVAX) rose more than 5% in pre-market trading on Wednesday, as investors welcomed a first-quarter earnings beat powered by a sharp surge in the high-margin licensing and royalty revenue, which more than doubled from a year earlier.Total revenue for the first quarter (Q1) of 2026 fell to $140 million, but came above analysts’ estimates of roughly $81 million, according to Fiscal.ai. Revenue last year was heavily driven by a $603 million in non-cash revenue from closing out two advance purchase agreements for its Nuvaxovid COVID-19 vaccine.Q1 net loss&nbsp;came in at $9 million, or a loss of $0.06 per share, significantly narrower than the 0.23 per share estimate.<h2 class="st-heading-2">Pfizer Deal Highlights Platform Value&nbsp;</h2>The company is increasingly leaning on partnerships and licensing agreements tied to its vaccine technology to fuel growth.In January, Novavax secured $30 million upfront from Pfizer (PFE) upon licensing its Matrix-M adjuvant, with the potential for up to an additional $500 million in development and sales milestones. Novavax also stands to earn mid- to high-single-digit royalties on future product sales using the technology.<h2 class="st-heading-2">NVAX’s Key Growth Engine: Licensing And Royalties&nbsp;</h2>The firm’s strategy is gaining strong traction as its partners begin exploring applications across more than half of the global vaccine and immunotherapy market, which is expected to exceed $100 billion by the early 2030s.Overall, its licensing, royalties, and other revenue rose to $97 million in Q1, up from $45 million a year earlier.<h2 class="st-heading-2">Cost Cuts In Focus Amid Activist Investor Pressure</h2>Last month, activist investor Shah Capital pushed for changes at the vaccine maker, calling on management to cut expenses and consider buying back 10-20 million shares.The company said it is already working to lower costs, aiming for about $325 million in combined research and administrative spending in 2026, and around $225 million in 2027.<h2 class="st-heading-2">NVAX Stock: What Did Retail Traders Say?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user highlighted the company’s strong IP and its potential to boost an acquisition.<stembedurl>https://stocktwits.com/ajbski/message/652422923</stembedurl>Another user said, “It’s the only thing that matters,” highlighting a headline talking about the company’s strength in vaccine deals.<stembedurl>https://stocktwits.com/Bodu/message/652421649</stembedurl>The stock has gained 20% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oscr-stock-jumps-profit-surge-retail-bullish/cZQzdxSReaD">OSCR Stock Pops Pre-Market On Record Quarterly Income – Retail Traders Say ‘Still Undervalued’ Even At $30</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Tops Expectations On High-Margin Deals – Retail Says ‘It’s The Only Thing That Matters’

Total revenue for the first quarter fell to $140 million, but came above analysts’ estimates of roughly $81 million, according to Fiscal.ai data.

NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch

Equity

Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

Novavax (NVAX) to Release Earnings on Wednesday

Novavax (NASDAQ:NVAX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-novavax-inc-stock...

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Novavax (NVAX) concluded the recent trading session at $8.01, signifying a +1.01% move from its prior day's close.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 PR Newswire GAITHERSBURG, Md., April 29, 2026 GAITHERSBURG...

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know  

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

$NVAX Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.06 down -101.86% YoY
• Reported revenue of $139.51M down -79.07% YoY

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.06 down -101.86% YoY
• Reported revenue of $139.51M down -79.07% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits Polls

Investors are surging over the expanded Matrix-M platform, with 4 major pharma MTAs and oncology-focused licensing fueling high-growth expectations.

High short interest and days-to-cover metrics have traders speculating that a major earnings beat could force aggressive short-covering and fuel a rally.

Buzz is building around the clinical advancement of a potential C. difficile blockbuster vaccine candidate, seen as a game-changer for future pipeline value.

Tensions remain high as investors debate the efficacy of leadership, with calls for activist intervention and executive accountability ahead of the board vote.

Current Price	$9.14
Prev Close	$8.10
Open	$8.61
Dividend Yield	0.00%
50-Day Moving Average	$9.04
Beta	1.41
Avg. Volume	3M
PE Ratio	3.40

52-Week High	$11.97
52-Week Low	$5.80
Market Capitalization	$1.31B
EPS (Annual)	$2.54
Price to Book	-10.31
Revenue Per Employee	$1.5M

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAXNovavax Inc